within Pharmacolibrary.Drugs.ATC.L;

model L01BC02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.7166666666666667,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fluorouracil (5-FU) is an antimetabolite chemotherapy drug for cancers such as colorectal and breast cancer, disrupting DNA synthesis by inhibiting thymidylate synthase. Approved and commonly used intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adults receiving continuous IV infusion.</p><h4>References</h4><ol><li>R B Diasio, B E Harris,Clinical pharmacology of 5-fluorouracil.,Clinical pharmacokinetics,1989<a href='https://pubmed.ncbi.nlm.nih.gov/2656050/'>https://pubmed.ncbi.nlm.nih.gov/2656050/</a></li><li>Olga V Zhukova, Natalya A Dubovskaya, Daria A Zykova, Evgenia V Arkhipova, Olga A Vorobeva, Olga G Zaborskaya, Sergey D Zaitsev, Alexandra O Grigoreva, Aleksandr A Chicharov, Sergey A Ryabov,Specifics of Pharmacokinetics and Biodistribution of 5-Fluorouracil Polymeric Complex.,Molecules (Basel, Switzerland),2023<a href='https://pubmed.ncbi.nlm.nih.gov/38138585/'>https://pubmed.ncbi.nlm.nih.gov/38138585/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BC02_1;
